Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 10Other hematologic neoplasm 8Classical hematology 3Thoracic 2Sarcoma 2Plasma cell 2Myeloid 2Other solid neoplasm 1Genitourinary 1Breast 1

Conditions

Solid Tumors 1

Interventions

pembrolizumab 77Injections 67Carboplatin 38Nivolumab 31Pemetrexed 29Cisplatin 29Cyclophosphamide 25Specimen Handling 24Interviews as Topic 24tislelizumab 20atezolizumab 20Bevacizumab 20Paclitaxel 19fludarabine 16Standard of Care 16Practice Guidelines as Topic 16Docetaxel 16Ipilimumab 15toripalimab 14Educational Status 14Cetuximab 14Fluorouracil 13Oxaliplatin 12Etoposide 12olaparib 11durvalumab 11Methods 11Gemcitabine 11Early Intervention, Educational 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
pegylated granulocyte colony-stimulating factor × Other solid neoplasm × 1 year × Clear all
NCT06926751 2026-05-07

Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
132 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡